| Under the terms of the agreement, Shasun grants Merck the use of its proprietary cross-coupling copper technology (also known as Buchwald technology) to manufacture and commercialize API's (Active Pharmaceutical Ingredients). The Buchwald cross-coupling technology is one of the most popular technologies in the pharmaceutical area allowing increasingly complex new drugs to be manufactured in an efficient and economical way. |
| Commenting on this development, Dr. Michel Spagnol (Chief Technology Officer) said, "I am very excited to have finalized this agreement with Merck. This is an important milestone for Shasun in making this technology widely accessible and paving the way for further collaborations." |
| Mr. Govindarajan (CEO and Managing Director of Shasun) added "This is yet another example that demonstrates Shasun's commitment to developing and commercializing its expanding portfolio of cutting edge technologies." |
| About Shasun Chemicals & Drugs Ltd (BSE: 524552, NSE: SHASUNCHEM) |
| Shasun Chemicals and Drugs Ltd., India is a premier service provider to the pharmaceutical industry. It was founded in 1976 and its headquarters are in Chennai, Tamilnadu, India. With the maiden acquisition of business and assets of UK-based Rhodia Pharma through the wholly owned subsidiary Shasun Pharma Solutions Ltd (SPSL), Shasun has now become a multi national company. For further information, please visit www.shasun.com |
Top Section
Explore Business Standard